"Cynata and Fujifilm intend that Fujifilm will have first rights to manufacture clinical and commercial requirements for Cymerus therapeutic MSC products. In addition, and in recognition of the progress made by Fujifilm, Cynata will pay Fujifilm a proportion of any upfront licence fee received by Cynata if Cynata approves main terms of a GvHD licence agreement with certain third parties within the next 6 months. "
Completely out of context and nothing to do with running our own GvHD trial. Your lack of knowledge leads you to make continued stupid assumptions. (never happen, no office, no money.. etc) This was a clause for Fuji IF CYP partnered GvHD within 6 months to claw back some $.
Your stupidity on the GvHD P2 trial will come back to haunt you all 2023. and I'll be here reminding you of such.
CYP Price at posting:
32.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
.
(20min delay)